Kalaris Therapeutics Inc(KLRS)

Biotechnology · Berkeley Heights, NJ

$2.82-0.02 (-0.53%)

Delayed quote: Oct 6, 2026, 1:53 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T17:57:06.891Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:57:06.891Z.

Quote observation: 2026-10-06T17:53:21.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 61,444,491
Total debt · period ending 2026-06-30: 1,400,000
Cash · period ending 2026-06-30: 43,173,000
TTM operating income · period ending 2026-06-30: -47,761,000

FMP input reference: 93c5e63ae445a2e41424364838d154d4df2cbb6a4085a726ee5a5ae15b1ce67b

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KLRS EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

KLRS Competitors' EV/EBIT Ratio

KLRS

Kalaris Therapeutics Inc

Current

Market Cap

$61.44M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ONCY

Oncolytics Biotech Inc.

vs KLRS

Market Cap

$60.21M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GUTS

Fractyl Health, Inc.

vs KLRS

Market Cap

$62.69M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XLO

Xilio Therapeutics, Inc.

vs KLRS

Market Cap

$60.03M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLRX

Pliant Therapeutics, Inc.

vs KLRS

Market Cap

$63.16M

EV/EBIT Ratio

N/A

TTM Avg

31.50x

3Y Avg

31.50x

5Y Avg

31.50x

ALPS

Alps Group Inc

vs KLRS

Market Cap

$63.25M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HRTX

Heron Therapeutics, Inc.

vs KLRS

Market Cap

$63.41M

EV/EBIT Ratio

N/A

TTM Avg

237.48x

3Y Avg

237.48x

5Y Avg

237.48x

ACET

Adicet Bio, Inc.

vs KLRS

Market Cap

$59.36M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNTB

Connect Biopharma Holdings Limited

vs KLRS

Market Cap

$59.41M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INCR

InterCure Ltd.

vs KLRS

Market Cap

$63.79M

EV/EBIT Ratio

N/A

TTM Avg

9.73x

3Y Avg

23.03x

5Y Avg

21.55x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Kalaris Therapeutics Inc (KLRS)	$61.44M	N/A	N/A	N/A	N/A
Oncolytics Biotech Inc. (ONCY)vs ›	$60.21M	N/A	N/A	N/A	N/A
Fractyl Health, Inc. (GUTS)vs ›	$62.69M	N/A	N/A	N/A	N/A
Xilio Therapeutics, Inc. (XLO)vs ›	$60.03M	N/A	N/A	N/A	N/A
Pliant Therapeutics, Inc. (PLRX)vs ›	$63.16M	N/A	31.50x	31.50x	31.50x
Alps Group Inc (ALPS)vs ›	$63.25M	N/A	N/A	N/A	N/A
Heron Therapeutics, Inc. (HRTX)vs ›	$63.41M	N/A	237.48x	237.48x	237.48x
Adicet Bio, Inc. (ACET)vs ›	$59.36M	N/A	N/A	N/A	N/A
Connect Biopharma Holdings Limited (CNTB)vs ›	$59.41M	N/A	N/A	N/A	N/A
InterCure Ltd. (INCR)vs ›	$63.79M	N/A	9.73x	23.03x	21.55x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

KLRS EV/EBIT Ratio Metrics

KLRS Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics